GÜLSÜM AKGÜN ÇAĞLIYAN, OKTAY BİLGİR

Erişkin yaşta tanı alan Gaucher hastalıklı bir olgu

Gaucher hastalığı, dalak karaciğer ve kemik iliğinde glukozilseramid birikimi ile karakterizedir. Hastalık otozomal resesif geçer ve lizozomal lipid depo hastalığıdır. Glukozilseramid hidrolaz (b-glukozidaz)da genetik defekt sonucu retikuloendoteliyal sistem hücrelerinin lizozomlarda glukoseramid birikir. Gaucher hastalığında masif splenomegali ve sitopeniler görülür. 37 yaşında sitopeniler ve hepatosplenomegali nedeniyle hastanemize başvuran ve erişkin yaşta Gaucher hastalığı tanısı alan olgu sunuldu.

A case of gaucher disease diagnosed at adult age

Gaucher disease is characterized by the deposit of glucosylceramide in the spleen, liver and bone marrow. This lipid lysosomal storage disease shows autosomal recessive inheritance and. Glucosylceramide is stored in lysosomal bodies of the cells of the reticuloendothelial system as a result of a genetic defect in glucosylceramide hydrolase (b- glucosidase). Massive splenomegaly and cytopenias are seen in Gaucher disease. We presented a 37-year-old woman admitted to our hospital with cytopenias and splenomegaly and diagnosed as Gaucher disease in adult age.

PDF

___

1. Beulter E. Gaucher disease: Multipl lessons from a single gene disorder. Acta Paediatr 2006;95(451):103-9.
2. Grabowski GA, Andria G, Baldellou A, et al. Gaucher disease: Presentation, diagnosis and assessment. Eur J Pediatr 2004;163(2):58-66.
3. Zimran A, Altarescu G, Rudensky B, Abrahamov A, Elstein D. Survey of hematological aspects of Gaucher diseases. Hematology 2005;10(2):151-6.
4. Kannai R, Chertok IR. Prenatal panel screening considerations for non-neuronopathic Gaucher disease in the Ashkenazi- Jewish population. Isr Med Assoc J 2006;8(5):347-50.
5. Wenstrup RJ, Roca Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: A review. Br J Radiol 2002;75 Suppl 1:A2-12.
6. Mignot C, Doummar D, Marie I, De Villemeur TB. French Type 2 Gaucher Disease Study Group. Type 2 Gaucher Disease: 15 new cases and review of the literature. Brain Dev 2006;28(1):39-48.
7. Germain DP. Gaucher disease: clinical , genetic and therapeutic aspects. Pathol Biol 2004;52(6):343-50.
8. Kaminsky P,Lidove O. Current therapeutic strategies in lysosomal disorder. Presse Med 2014;43(11):1174-84.
9. Van Dussen L, Biegstraaten M, Hollak Ce, Dijkqraaf MG. Cost-effectiveness of enzyme replacement therapy for Type 1 Gaucher disease. Orphanet J Rare Dis 2014 14;9(1):51.
10. Lecourt S, Mouly E, Freida D, et al. A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients. PloS One 2013 Jul 25;8(7):e69293.